Inc Nasdaq

• NanoViricides, Inc. (NASDAQ:NNVC) has announced the launch of a Phase II clinical trial for NV-387, an oral gummy treatment designed to combat Ebola viruses. • The trial is being conducted in the Democratic Republic of the Congo (DRC) and is led by Prof. Patrick Katoto, a distinguished researcher and Fogarty Fellow. • This medical intervention is a direct response to the growing Bundibugyo outbreak, aiming to provide a scalable treatment option in a high-risk region.

• NanoViricides, Inc. (NASDAQ:NNVC) has received regulatory approval to initiate a Phase II Clinical Trial for NV-387 oral gummies. • The drug is being developed as a treatment for the Bundibugyo Ebola virus, addressing an urgent need for effective antivirals during the current outbreak in the Democratic Republic of the Congo. • This trial offers a potentially faster alternative to the PARTNERS clinical trial, which requires over 1,000 patients and may take more than a year to yield results.

• NanoViricides, Inc. (NASDAQ:NNVC) has received regulatory approval to initiate a Phase II Clinical Trial for NV-387 oral gummies designed to treat the Bundibugyo Ebola virus. • The trial addresses an urgent need for effective antiviral drugs amid a current outbreak in the Democratic Republic of Congo (DRC). • This development is critical because existing FDA-approved antibody drugs for EBOV Zaire are not considered effective for the Bundibugyo strain without further testing.

• S&P 500 and Nasdaq futures rose slightly on Monday, August 10, as investors monitored geopolitical tensions in the Middle East. • Iran reported it is nearing a final agreement with Oman to define new shipping lanes through the Strait of Hormuz, though it maintains that the U.S. must meet specific conditions before the waterway reopens. • Restoring energy flows through this strategic choke point is critical to mitigating oil price spikes, which have previously fueled global inflation and increased the likelihood of central bank interest rate hikes.

• The S&P 500 and Nasdaq concluded June with their strongest quarterly gains since 2020, marking a significant rally for U.S. equity markets. • Investors maintained an upbeat outlook on economic and earnings growth, allowing indices to rise despite geopolitical instability and the conflict in the Middle East. • This performance highlights the market's current resilience and a high tolerance for risk among investors facing global tensions.

• The S&P 500 and Nasdaq declined for the third consecutive day on June 24, 2026, driven by renewed selling pressure in the technology sector. • AI chip designer Cerebras (CBRS) saw its shares tumble 20% following its first public earnings report, which forecast a gross margin contraction of up to 10 percentage points this quarter. • Oil prices dropped to their lowest level since the start of the war, while FedEx (FDX) shares dipped slightly despite reporting quarterly results that beat Wall Street estimates.

• The Dow, S&P 500, and Nasdaq reached record highs in May, though markets experienced a slight dip early Monday. • Positive momentum was driven by optimism surrounding US-Iran peace talks and the release of a new laptop chip from Nvidia (NVDA). • Economic data showed the ISM manufacturing gauge rose to 54, surpassing both April's reading of 52.7 and economist predictions of 53.